(NASDAQ: ZBIO) Zenas Biopharma's forecast annual revenue growth rate of 102.07% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.05%.
Zenas Biopharma's revenue in 2026 is $10,000,000.On average, 9 Wall Street analysts forecast ZBIO's revenue for 2026 to be $1,037,263,665, with the lowest ZBIO revenue forecast at $0, and the highest ZBIO revenue forecast at $4,271,062,058. On average, 9 Wall Street analysts forecast ZBIO's revenue for 2027 to be $2,961,332,409, with the lowest ZBIO revenue forecast at $1,306,402,697, and the highest ZBIO revenue forecast at $4,938,402,957.
In 2028, ZBIO is forecast to generate $4,702,418,734 in revenue, with the lowest revenue forecast at $1,665,254,739 and the highest revenue forecast at $6,075,704,659.